StemRIM
4599
Rank in Stocks
#23118
StemRIM is a biotechnology firm dedicated to developing regenerative medicines... StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
Share Price
$0.72791031
Last synced: 2026-11-10
Market Cap
$45.63M
Change (1 day)
-0.86%
Change (1 year)
-59.66%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade StemRIM (4599)
Category
Healthcare
Operating Margin for StemRIM (4599)
Operating Margin as of November 2026 TTM: 0.00%
According to StemRIM's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for StemRIM from 2017 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | -100.00% |
| 2023 | 6.06% | -100.07% |
| 2022 | -8,620.68% | 20,227.00% |
| 2021 | -42.41% | -314.19% |
| 2020 | 19.80% | -102.72% |
| 2019 | -726.86% | 287.51% |
| 2018 | -187.57% | 250.01% |
| 2017 | -53.59% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about StemRIM's operating margin
What was StemRIM's operating margin in 2025?
In 2025, StemRIM's operating margin was 0.00%, compared with 0.00% in 2024.
How has StemRIM's operating margin changed since 2020?
From 2020 to 2025, StemRIM's operating margin was highest in 2020 (19.80%) and lowest in 2022 (-8,620.68%).
How does StemRIM's operating margin compare with similar companies?
StemRIM's operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.